Navigation Links
Neuralstem President And CEO To Present 2014 Trials Overview At 2014 Biotech Showcase
Date:1/13/2014

ROCKVILLE, Md., Jan. 13, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the sixth annual Biotech Showcase (http://www.ebdgroup.com/bts/index.php) in San Francisco on Tuesday, January 14, 3:30 p.m. PT, in Room Powell (Track D). Garr will present a business overview, including updates on ongoing and planned clinical trials. Garr will provide a progress update on NSI-566 cell therapy trials including ALS Phase II, chronic spinal cord injury Phase I, and ischemic stroke Phase I/II in China. Garr will also update the status of its neurogenic NSI-189 small molecule drug which stimulates new neuron growth in the hippocampus, which completed a Phase I safety trial, in major depressive disorder, in the fourth quarter of 2013.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

The audio webcast will be available in real-time at http://www.media-server.com/m/p/p65iz6pt, with replay beginning approximately two hours following the presentation, and archived for one year. The webcast link will also be posted on the Investor Center home page on Neuralstem's website: www.neuralstem.com.

About Neuralstem

Neuralstem's patented technology enables the production of neural stem cells of the brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glial cells. Neuralstem's NSI-566 spinal cord-derived stem cell therapy is in Phase II clinical trials for amyotrophic lateral sclerosis (ALS), often referred to as '/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neuralstem Reports Third Quarter Financial Results And Provides Business And Clinical Update
2. Neuralstem President And CEO To Present At The 2013 Rodman & Renshaw Annual Healthcare Conference
3. Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
4. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
5. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
6. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
7. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
8. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
9. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
10. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
11. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... 29, 2015 , ... Finding gooey or crusty material in the corner of ... a considerable number of terms in popular use to describe it, ophthalmologists call it ... of mucus, blood cells, skin cells and dust, but until now there has been ...
(Date:7/29/2015)... FRANCE (PRWEB) , ... July 29, 2015 , ... ... Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel, a nighttime-specific product that ... the amount of sugars that are able to enter fat cells, inhibiting the ...
(Date:7/29/2015)... Windsor, CT (PRWEB) , ... July 29, 2015 ... ... of Biological Industries’ (BI) advanced cell culture products, announces the availability of BI’s ... Recently launched by Biological Industries, these stem cell differentiation media offer a complete ...
(Date:7/29/2015)... ... , ... Nearly everyone has heard of the potential of stem cells to ... source of these cells is teeth—baby teeth that come loose during childhood, wisdom teeth ... make room for braces. These potent stem cells exist in the dental pulp ...
Breaking Biology Technology:What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Tooth™ Dental Stem Cell Banking Available to their Patients 2
... Initiation Dosing Regimen , , ... investigational long-acting therapy (LAT) demonstrated statistically significant symptom control ... 13-week study presented today (1). Statistical significance was ... mg equivalent [eq.a]), when given every 4 weeks with ...
... VIASPACE Inc. (OTC Bulletin Board: VSPC) announced today that ... Giant King Grass near the IPA factory in Guangdong province in ... which is propagated from seedlings rather than seeds. In tropical ... crops per year and up to 156 tons of grass per ...
... Advances , ... Ann Arbor, MI (PRWEB) December 10, 2008 -- A ... flexibility and comfort in engineering, assembly, laboratory and inspection applications. , ,The ... Ann Arbor, Mich., uses a ring of 60 lights and a 3-diopter ...
Cached Biology Technology:Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 2Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 3Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 4Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 5Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 6Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 7Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 8Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia 9VIASPACE Plants Biofuel & Animal Feed Grass and Signs Land Lease in China 2VIASPACE Plants Biofuel & Animal Feed Grass and Signs Land Lease in China 360 LED Lights Enhance Magnifying Lamp for Assembly, Engineering, Inspection or Research 260 LED Lights Enhance Magnifying Lamp for Assembly, Engineering, Inspection or Research 3
(Date:7/21/2015)... 21, 2015 Passwords have proven futile ... the recent U.S. Office of Personnel Management breach. ... infosec conundrum, but developers and end-users are concerned ... this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today ... for third party integration. A ...
(Date:7/9/2015)... SAN JOSE, Calif. , July 9, 2015 /PRNewswire/ ... human interface solutions, announced today that it will report ... 2015 on Thursday, July 30, 2015 after the close ... call for analysts and investors at 2:00 p.m. PT ... information.    To participate on the live ...
(Date:7/8/2015)... July 8, 2015 Summary Pancreatic cancer ... fourth most fatal, with a mortality rate of 10.9 ... of pancreatic cancer patients has highlighted a significant need ... not being met by the current market. A ... products with varying molecule types and mechanisms of action, ...
Breaking Biology News(10 mins):HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... An international team of scientists report on the first ... an ever-changing environment inside Earth,s crust. University of Miami ... Keir Becker contributed the deep-sea technology required to make ... During the four-year subsurface experiment, the ...
... MARIETTA, Ga., April 11, 2011 MiMedx Group, Inc. ... patent protected biomaterial-based products and bioimplants processed from human ... Company,s latest product, EpiFix™, a biologic implant specifically processed ... wound care options. The Company also announces the hiring ...
... teacher for a young mother is her baby, contend experts ... "We like to think of babies as ,ordinary miracles," said ... Service Administration at the University of Chicago. But adjusting to ... workers often is to help young mothers learn to focus ...
Cached Biology News:What lies beneath the seafloor? 2MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 2MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 3MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 4New mothers can learn a lot from watching their babies 2New mothers can learn a lot from watching their babies 3
Porcine Aortic Smooth Muscle Cells (PAOSMC) (>500,000 cells)...
... IV Recognizes an epitope located ... β-tubulin isotype IV. No reactivity ... observed. ascites fluid synthetic peptide ... of β-tubulin isotype IV, conjugated ...
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
Porcine Aortic Endothelial Cells (PAOEC) (>500,000 cells)...
Biology Products: